Related Party Transactions	3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions As described in Note 11, in July 2021, the Company entered into the 2021 License Agreement with NHSc Pharma Partners, succeeded by NHSc Rx License GmbH (together with Société des Produits Nestlé S.A., their affiliates, and their subsidiaries, “Nestlé”). NHSc Rx License GmbH is an affiliate of one of the Company's significant stockholders, Société des Produits Nestlé S.A. During the three months ended March 31, 2023 and 2022, the Company recognized $1,122 and $768, respectively, of related party revenue associated with the 2021 License Agreement. As of March 31, 2023 and December 31, 2022, there was $854 and $1,976 of deferred revenue related to the 2021 License Agreement, respectively, which is classified as current in the condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022 there was $24,958 and $34,770 included in accrued expenses and other liabilities related to the 2021 License Agreement. During the three months ended March 31, 2023, the Company paid Nestlé $13,419 for Nestlé's share of the collaboration expenses pursuant to the 2021 License Agreement. The Company made no payments to Nestlé during the three months ended March 31, 2022. There is no amount due from Nestlé pursuant to the 2021 License Agreement as of March 31, 2023 or December 31, 2022. As described in Note 11, in January 2016, the Company entered into the 2016 License Agreement with Nestec, Ltd, succeeded by Société des Produits Nestlé S.A. for the development and commercialization of certain product candidates in development for the treatment and management of CDI and IBD, including UC and Crohn’s disease. Société des Produits Nestlé S.A. is one of the Company's significant stockholders. During the three months ended March 31, 2023 and 2022, the Company recognized $(1,644) and $725, respectively, of related party revenue associated with the 2016 License Agreement. As of March 31, 2023 and December 31, 2022, there was $96,357 and $94,713 of deferred revenue related to the 2016 License Agreement, which is classified as current or non-current in the condensed consolidated balance sheets. The Company has made no payments to Nestlé during the three months ended March 31, 2023 and 2022. There is no amount due from Nestlé pursuant to the 2016 License Agreement as of March 31, 2023 or December 31, 2022.

Related Party Transactions

3 Months Ended

Mar. 31, 2023

13. Related Party Transactions

As described in Note 11, in July 2021, the Company entered into the 2021 License Agreement with NHSc Pharma Partners, succeeded by NHSc Rx License GmbH (together with Société des Produits Nestlé S.A., their affiliates, and their subsidiaries, “Nestlé”). NHSc Rx License GmbH is an affiliate of one of the Company's significant stockholders, Société des Produits Nestlé S.A. During the three months ended March 31, 2023 and 2022, the Company recognized $1,122 and $768, respectively, of related party revenue associated with the 2021 License Agreement. As of March 31, 2023 and December 31, 2022, there was $854 and $1,976 of deferred revenue related to the 2021 License Agreement, respectively, which is classified as current in the condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022 there was $24,958 and $34,770 included in accrued expenses and other liabilities related to the 2021 License Agreement. During the three months ended March 31, 2023, the Company paid Nestlé $13,419 for Nestlé's share of the collaboration expenses pursuant to the 2021 License Agreement. The Company made no payments to Nestlé during the three months ended March 31, 2022. There is no amount due from Nestlé pursuant to the 2021 License Agreement as of March 31, 2023 or December 31, 2022.

As described in Note 11, in January 2016, the Company entered into the 2016 License Agreement with Nestec, Ltd, succeeded by Société des Produits Nestlé S.A. for the development and commercialization of certain product candidates in development for the treatment and management of CDI and IBD, including UC and Crohn’s disease. Société des Produits Nestlé S.A. is one of the Company's significant stockholders. During the three months ended March 31, 2023 and 2022, the Company recognized $(1,644) and $725, respectively, of related party revenue associated with the 2016 License Agreement. As of March 31, 2023 and December 31, 2022, there was $96,357 and $94,713 of deferred revenue related to the 2016 License Agreement, which is classified as current or non-current in the condensed consolidated balance sheets. The Company has made no payments to Nestlé during the three months ended March 31, 2023 and 2022. There is no amount due from Nestlé pursuant to the 2016 License Agreement as of March 31, 2023 or December 31, 2022.